Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 205 articles:
HTML format
Text format



Single Articles


    May 2017
  1. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Text format     Abstract available


  2. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Text format     Abstract available


  3. WANG CC, Kao JH
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2017 May 8. doi: 10.1002/hep.29252.
    PubMed     Text format    


  4. MAILLY L, Zeisel MB, Baumert TF
    Towards novel immunocompetent animal models for hepatitis B virus infection.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29249.
    PubMed     Text format    


  5. LI W, Amet T, Xing Y, Yang D, et al
    Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29242.
    PubMed     Text format     Abstract available


    April 2017
  6. LOUVET A, Labreuche J, Artru F, Bouthors A, et al
    Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: A prospective study.
    Hepatology. 2017 Apr 29. doi: 10.1002/hep.29240.
    PubMed     Text format     Abstract available


  7. DIAB AM, Foca A, Fusil F, Lahlali T, et al
    Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.
    Hepatology. 2017 Apr 26. doi: 10.1002/hep.29236.
    PubMed     Text format     Abstract available


  8. MIN AD
    Low-level viremia in hepatitis B patients on antiviral treatment: Can we ignore it?
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29235.
    PubMed     Text format    


  9. BARGE S, Ziol M, Nault JC
    Autoimmune-like chronic hepatitis induced by olmesartan.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228.
    PubMed     Text format     Abstract available


  10. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed     Text format    


  11. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available


  12. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


  13. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed     Text format    


  14. CHANG ML, Liaw YF
    Overt acute hepatitis B is more severe in female patients.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29196.
    PubMed     Text format    


  15. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Text format     Abstract available


  16. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed     Text format    


    March 2017
  17. FUNG J, Wong T, Chok K, Chan A, et al
    Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years.
    Hepatology. 2017 Mar 31. doi: 10.1002/hep.29191.
    PubMed     Text format     Abstract available


  18. LIM YS, Lee YS, Gwak GY, Byun KS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29187.
    PubMed     Text format     Abstract available


  19. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed     Text format    


  20. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed     Text format    


  21. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  22. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  23. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  24. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  25. KOSINSKA AD, Pishraft-Sabet L, Wu W, Fang Z, et al
    Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.
    Hepatology. 2017 Mar 13. doi: 10.1002/hep.29155.
    PubMed     Text format     Abstract available


  26. STELMA F, van der Ree MH, Sinnige MJ, Brown A, et al
    Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101.
    Hepatology. 2017 Mar 11. doi: 10.1002/hep.29148.
    PubMed     Text format     Abstract available


  27. HEZODE C, Colombo M, Bourliere M, Spengler U, et al
    Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29139.
    PubMed     Text format     Abstract available


    February 2017
  28. BELPERIO PS, Shahoumian TA, Mole LA, Backus LI, et al
    Evaluation of Hepatitis B Reactivation among 62,920 Veterans treated with Oral Hepatitis C Antivirals.
    Hepatology. 2017 Feb 27. doi: 10.1002/hep.29135.
    PubMed     Text format     Abstract available


  29. YAN F, Wang Y, Zhang W, Chang M, et al
    Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29134.
    PubMed     Text format     Abstract available


  30. ZHANG W, Chen J, Wu M, Zhang X, et al
    PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29133.
    PubMed     Text format     Abstract available


  31. LAWITZ E, Poordad F, Wells J, Hyland RH, et al
    Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
    PubMed     Text format     Abstract available


  32. HOGAN JJ, Lim MA, Palmer MB, Bloom RD, et al
    Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1).
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29125.
    PubMed     Text format     Abstract available


  33. SABERI B, Dadabhai AS, Durand CM, Philosophe B, et al
    Challenges in Treatment of Hepatitis C among Patients with Hepatocellular Carcinoma.
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126.
    PubMed     Text format    


  34. XU L, Wang W, Li Y, Zhou X, et al
    RIG-I Is A Key Antiviral Interferon-Stimulated Gene Against Hepatitis E Virus Dispensable Of Interferon Production.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29105.
    PubMed     Text format     Abstract available


  35. LEMPP FA, Wiedtke E, Qu B, Roques P, et al
    Sodium taurocholate cotransporting polypeptide is the limiting host factor of Hepatitis B Virus infection in macaque and pig hepatocytes.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29112.
    PubMed     Text format     Abstract available


  36. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  37. CHEN G, Wang C, Chen J, Ji D, et al
    Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29109.
    PubMed     Text format     Abstract available


  38. DENOLLY S, Cosset FL
    A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29066.
    PubMed     Text format    


  39. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  40. CARTER L, Aronsohn A
    Overcoming Injustice: A Roadmap to Improve Access to HCV Therapy for Our Medicaid Patients.
    Hepatology. 2017 Feb 4. doi: 10.1002/hep.29095.
    PubMed     Text format    


  41. OLIVEIRA C, Fournier C, Descamps V, Morel V, et al
    Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles.
    Hepatology. 2017 Feb 2. doi: 10.1002/hep.29096.
    PubMed     Text format     Abstract available


    January 2017
  42. PAUL S, Dickstein A, Saxena A, Terrin N, et al
    Role of Surface Antibody in Hepatitis B Reactivation in Patients with Resolved Infection and Hematologic Malignancy: A Meta-Analysis.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29082.
    PubMed     Text format     Abstract available


  43. POORDAD F, Felizarta F, Asatryan A, Sulkowski MS, et al
    Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081.
    PubMed     Text format     Abstract available


  44. BISSONNETTE J, Altamirano J, Devue C, Roux O, et al
    A Prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29080.
    PubMed     Text format     Abstract available


  45. SHIMIZU Y, Peltzer N, Sevko A, Lafont E, et al
    The linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29074.
    PubMed     Text format     Abstract available


  46. BERENGUER J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, et al
    Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071.
    PubMed     Text format     Abstract available


  47. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069.
    PubMed     Text format    


  48. SMITH J, Rich J
    Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070.
    PubMed     Text format    


  49. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Text format     Abstract available


  50. BOYD A, Miailhes P, Lacombe K, Zoulim F, et al
    Potential effect of lamivudine-induced S-gene mutations on liver-related pathogenesis in hepatitis D virus infection.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29062.
    PubMed     Text format    


  51. O'BRIEN TR, Kottilil S, Feld JJ, Morgan TR, et al
    Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29057.
    PubMed     Text format    


  52. SU F, Ioannou GN
    Reply to: Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29058.
    PubMed     Text format    


  53. VERNA EC
    The Dynamic Landscape of Liver Transplant in the Era of Effective HCV Therapy.
    Hepatology. 2017 Jan 17. doi: 10.1002/hep.29054.
    PubMed     Text format    


  54. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    PubMed     Text format     Abstract available


  55. HEI L, Zhong J
    LGP2 plays an essential role in HCV infection-induced interferon responses.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29050.
    PubMed     Text format     Abstract available


    December 2016
  56. SETO WK, Sau-Yan Chan T, Hwang YY, Wong DK, et al
    Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29022.
    PubMed     Text format     Abstract available


  57. LANTON T, Shriki A, Nechemia-Arbely Y, Abramovitch R, et al
    IL6-Dependent Genomic Instability Heralds Accelerated Carcinogenesis Following Liver Regeneration on a Background of Chronic Hepatitis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29004.
    PubMed     Text format     Abstract available


  58. KOWDLEY KV, Sundaram V, Jeon CY, Qureshi K, et al
    Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29005.
    PubMed     Text format     Abstract available


  59. SUN Y, Zhou J, Wang L, Wu X, et al
    New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29009.
    PubMed     Text format     Abstract available


  60. VIETHEER P, Boo I, Gu J, McCaffrey K, et al
    The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28989.
    PubMed     Text format     Abstract available


  61. BALISTRERI WF, Murray KF, Rosenthal P, Bansal S, et al
    The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 1 Infection.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28995.
    PubMed     Text format     Abstract available


  62. RUBIO-TAPIA A, Hujoel IA, Smyrk TC, Poterucha JJ, et al
    Emerging secondary syphilis presenting as syphilitic hepatitis.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28974.
    PubMed     Text format    


  63. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Text format     Abstract available


  64. PRICE JC, Ma Y, Scherzer R, Korn N, et al
    HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28968.
    PubMed     Text format     Abstract available


  65. ARTEMOVA M, Abdurakhmanov D, Ignatova T, Mukhin N, et al
    Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28981.
    PubMed     Text format    


    November 2016
  66. KENNEDY L, Francis H
    Defining the relationship between farsenoid X receptor, hepatitis B virus X protein and HCC: It's complicated.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28959.
    PubMed     Text format     Abstract available


  67. TSUKUDA S, Watashi K, Hojima T, Isogawa M, et al
    A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28952.
    PubMed     Text format     Abstract available


  68. LEVY PL, Duponchel S, Eischeid H, Molle J, et al
    Hepatitis C virus infection triggers a tumor-like glutamine metabolism.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28949.
    PubMed     Text format     Abstract available


  69. WANG L, Geng J
    Acute Hepatitis E Virus Infection in Patients with Acute Liver Failure in China: Not Quite an Uncommon Cause.
    Hepatology. 2016 Nov 10. doi: 10.1002/hep.28939.
    PubMed     Text format     Abstract available


  70. CHHATWAL J, Samur S, Kues B, Ayer T, et al
    Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28926.
    PubMed     Text format     Abstract available


  71. JOO EJ, Chang Y, Yeom JS, Ryu S, et al
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28917.
    PubMed     Text format     Abstract available


  72. NIU Y, Xu M, Slagle BL, Huang H, et al
    Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28924.
    PubMed     Text format     Abstract available


  73. PUNZEL M, Medd P, Hunter H, Cunningham R, et al
    Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony-stimulating factor treatment.
    Hepatology. 2016;64:1803-1805.
    PubMed     Text format    


    October 2016
  74. QIN G, Zhuang X
    Cost-Effectiveness of Augmenting Current Perinatal Hepatitis B Prevention Program with Maternal Antiviral Therapy.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28904.
    PubMed     Text format    


  75. SU F, Green PK, Berry K, Ioannou GN, et al
    The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28901.
    PubMed     Text format     Abstract available


  76. DAS S, Maras JS, Hussain S, Sharma S, et al
    Hyperoxidized Albumin Modulates Neutrophils to Induce Oxidative Stress and Inflammation in Severe Alcoholic Hepatitis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28897.
    PubMed     Text format     Abstract available


  77. LAWITZ E, Poordad F, Gutierrez JA, Wells JT, et al
    Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28877.
    PubMed     Text format     Abstract available


  78. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Text format     Abstract available


  79. BRADY JE, Liffmann DK, Yartel A, Kil N, et al
    Uptake of Hepatitis C Screening, Characteristics of Patients Tested, and Intervention Costs in the BEST-C Study.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28880.
    PubMed     Text format     Abstract available


  80. PIAO X, Yamazaki S, Komazawa-Sakon S, Miyake S, et al
    Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28878.
    PubMed     Text format     Abstract available


  81. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  82. CHENG JY, Wong VW, Tse YK, Chim AM, et al
    Metabolic syndrome increases cardiovascular event but not hepatic event and death in patients with chronic hepatitis B.
    Hepatology. 2016 Sep 29. doi: 10.1002/hep.28778.
    PubMed     Text format     Abstract available


  83. KLEPPER A, Eng FJ, Doyle EH, El-Shamy A, et al
    Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846.
    PubMed     Text format     Abstract available


  84. WANG RY, Bare P, De Giorgi V, Matsuura K, et al
    Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28842.
    PubMed     Text format     Abstract available


  85. KECK ZY, Wang Y, Lau P, Lund G, et al
    Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850.
    PubMed     Text format     Abstract available


  86. ROSEN HR
    "Hep C, where art thou": What are the remaining (fundable) questions in HCV research?
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28848.
    PubMed     Text format    


  87. NISHIO A, Tatsumi T, Nawa T, Suda T, et al
    CD14+ monocyte-derived Galectin-9 induces NK cell cytotoxicity in chronic hepatitis C.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28847.
    PubMed     Text format     Abstract available


  88. MITRA B, Guo H
    Hepatitis B Virus X Protein Crosses Out Smc5/6 Complex to Maintain cccDNA Transcription.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28834.
    PubMed     Text format    


  89. MARTINELLO M, Gane E, Hellard M, Sasadeusz J, et al
    Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28844.
    PubMed     Text format     Abstract available


  90. XIANG M, Liu T, Tan W, Ren H, et al
    Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on DCs-CD8+ T cells communication.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28825.
    PubMed     Text format     Abstract available


  91. HILL LA, Wyles DL
    Emerging complexities with HCV DAA regimens: Less is still way more.
    Hepatology. 2016 Sep 16. doi: 10.1002/hep.28832.
    PubMed     Text format    


  92. BROWN A, Halliday JS, Swadling L, Madden R, et al
    Characterisation of the specificity, functionality and durability of host T-cell responses against the full-length hepatitis E virus.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28819.
    PubMed     Text format     Abstract available


  93. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  94. WELLER R, Todt D, Engelmann M, Friesland M, et al
    Apolipoprotein E polymorphisms and their protective effect on Hepatitis E virus replication.
    Hepatology. 2016 Aug 19. doi: 10.1002/hep.28788.
    PubMed     Text format    


  95. TEO CG, Yesupriya A, Chang MH, Zhang L, et al
    "Apolipoprotein E polymorphisms and their protective effect on Hepatitis E virus replication" by Weller et al.
    Hepatology. 2016 Aug 19. doi: 10.1002/hep.28787.
    PubMed     Text format    


  96. DORE GJ
    Hepatitis C Treatment as Prevention among HIV-infected Men who have Sex with Men: Feasible?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28784.
    PubMed     Text format    


  97. SALAZAR-VIZCAYA L, Kouyos RD, Zahnd C, Wandeler G, et al
    Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28769.
    PubMed     Text format     Abstract available


  98. TAWAR RG, Heydmann L, Bach C, Schuttrumpf J, et al
    Broad neutralization of hepatitis C virus resistant variants by Civacir(R) hepatitis C immune globulin.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28767.
    PubMed     Text format     Abstract available


  99. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  100. LE GAL F, Brichler S, Sahli R, Chevret S, et al
    First International External Quality Assessment for Hepatitis Delta Virus RNA Quantification in Plasma.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28772.
    PubMed     Text format     Abstract available


  101. BANKWITZ D, Pietschmann T
    Hepatitis C virus plays hide and seek with neutralizing antibodies.
    Hepatology. 2016 Aug 12. doi: 10.1002/hep.28760.
    PubMed     Text format    


  102. SAYED IM, Vercouter AS, Meuleman P
    Hepatitis E virus in acute liver failure: An unusual suspect?
    Hepatology. 2016 Aug 6. doi: 10.1002/hep.28759.
    PubMed     Text format    


  103. PAWLOTSKY JM
    The end of the hepatitis C burden: Really?
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28758.
    PubMed     Text format    


  104. GRAGNANI L, Visentini M, Fognani E, Urraro T, et al
    Prospective Study of Guideline-Tailored Therapy with Direct-Acting Antivirals for Hepatitis C Virus-Associated Mixed Cryoglobulinemia.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28753.
    PubMed     Text format     Abstract available


  105. ABE-CHAYAMA H, Hayes CN, Chayama K
    Pan-genotypic cell culture system for propagation of hepatitis c virus clinical isolates.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28751.
    PubMed     Text format    


  106. BRAHM J, Castera L, Hou J, Lindor K, et al
    Joint society statement for the elimination of viral hepatitis.
    Hepatology. 2016 Aug 1. doi: 10.1002/hep.28730.
    PubMed     Text format    


    July 2016
  107. REGAN CP, Morissette P, Regan HK, Travis JJ, et al
    Preclinical Assessment of the Clinical Cardiac Drug-Drug Interaction Associated with the Combination of HCV-NI Antivirals and Amiodarone.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28752.
    PubMed     Text format     Abstract available


  108. DUSHEIKO G, Easterbrook P
    Bringing to an end mother to child transmission of hepatitis B: A role for quantitative HBsAg?
    Hepatology. 2016 Jul 25. doi: 10.1002/hep.28732.
    PubMed     Text format    


  109. SUGIYAMA M, Kanto T
    Dual blockade of HCV entry at a gatekeeper of hepatocytes - Not only a preventive but also therapeutic target of CLDN-1.
    Hepatology. 2016 Jul 12. doi: 10.1002/hep.28726.
    PubMed     Text format    



  110. Correction: A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.
    Hepatology. 2016;64:324.
    PubMed     Text format    


    June 2016
  111. ABERGEL A, Metivier S, Samuel D, Jiang D, et al
    Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28706.
    PubMed     Text format     Abstract available


  112. PRENTOE J, Velazquez-Moctezuma R, Foung SK, Law M, et al
    Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28705.
    PubMed     Text format     Abstract available


  113. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  114. SPENGLER EK, Kleiner DE, Fontana RJ
    Vemurafenib-induced Granulomatous hepatitis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28692.
    PubMed     Text format    


  115. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  116. ZHANG H, Xing Z, Mani SK, Bancel B, et al
    RNA helicase DDX5 regulates PRC2/HOTAIR function in Hepatitis B Virus infection and hepatocarcinogenesis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28698.
    PubMed     Text format     Abstract available


  117. THOMSEN MK, Nandakumar R, Stadler D, Malo A, et al
    Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28685.
    PubMed     Text format     Abstract available


  118. HUANG F, Li Y, Yu W, Jing S, et al
    Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis.
    Hepatology. 2016 Jun 10. doi: 10.1002/hep.28668.
    PubMed     Text format     Abstract available


  119. HU KQ, Cui W
    A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection.
    Hepatology. 2016 Jun 6. doi: 10.1002/hep.28663.
    PubMed     Text format     Abstract available


    May 2016
  120. SUNG FY, Lan CY, Huang CJ, Lin CL, et al
    Progressive accumulation of mutations in the hepatitis B virus genome and its impact for time to diagnosis of hepatocellular carcinoma.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28654.
    PubMed     Text format     Abstract available


  121. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  122. FONTANA RJ, Engle RE, Scaglione S, Araya V, et al
    The role of hepatitis E virus infection in Adult Americans with acute liver failure.
    Hepatology. 2016 May 23. doi: 10.1002/hep.28649.
    PubMed     Text format     Abstract available


  123. NATHANSON MH, Terrault N
    Hepatitis B surface antigen loss: Not all that we hoped it would be.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28640.
    PubMed     Text format    


  124. SCHREIBER J, McNally J, Chodavarapu K, Svarovskaia E, et al
    Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28636.
    PubMed     Text format    


  125. TOYODA H, Kumada T, Tada T
    Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
    Hepatology. 2016 May 2. doi: 10.1002/hep.28632.
    PubMed     Text format    


  126. PAPATHEODORIDIS G, Vlachogiannakos I, Cholongitas E, Wursthorn K, et al
    Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.
    Hepatology. 2016;63:1481-1492.
    PubMed     Text format     Abstract available


  127. SCHLEGEL M, Kohler D, Korner A, Granja T, et al
    The neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration.
    Hepatology. 2016;63:1689-705.
    PubMed     Text format     Abstract available


    April 2016
  128. FUJITA T
    Assessing endotoxemia in alcoholic hepatitis.
    Hepatology. 2016 Apr 28. doi: 10.1002/hep.28629.
    PubMed     Text format    


  129. ASIMAKOPOULOS A, Mangia A, Dore GJ, Lloyd AR, et al
    Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans.
    Hepatology. 2016 Apr 27. doi: 10.1002/hep.28626.
    PubMed     Text format    


  130. ZHOU YH
    Prevention of Mother-to-Child Transmission of Hepatitis B Virus by Treating Mothers with High Viral Loads.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28619.
    PubMed     Text format    


  131. HALFON P, Mohamed S, Penaranda G, Khiri H, et al
    Hepatitis c genotype 4r resistance associated polymorphisms: The achilles heel of the NS5A inhibitors?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28611.
    PubMed     Text format    


  132. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed     Text format    


  133. FOSCHI A, Casana M, Radice A, Ranieri R, et al
    CORRESPONDENCE: Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian Correctional Houses.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28609.
    PubMed     Text format    


  134. BACKUS LI, Belperio PS, Shahoumian TA, Loomis TP, et al
    Real World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment-Naive Genotype 1 Hepatitis C Infected Patients.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28625.
    PubMed     Text format     Abstract available


  135. MARTIN NK, Vickerman P, Hickman M
    CORRESPONDENCE: HCV testing and treatment in Italian prisons: Implications for prevention benefit and cost-effectiveness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28612.
    PubMed     Text format    


  136. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Text format     Abstract available


  137. WEN WH, Huang CW, Chie WC, Yeung CY, et al
    Quantitative Maternal Hepatitis B Surface Antigen Predicts Maternally Transmitted Hepatitis B Virus Infection.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28589.
    PubMed     Text format     Abstract available


  138. OZARAS R, Sunbul M, Parlak M, Bodur H, et al
    Treating HBV/HCV Co-infected Patients with Direct Acting HCV Antivirals Only is not Safe.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28592.
    PubMed     Text format    


  139. MANSUY JM, Gallian P, Dimeglio C, Saune K, et al
    A nationwide survey of hepatitis E viral infection in French blood donors.
    Hepatology. 2016;63:1145-54.
    PubMed     Text format     Abstract available


  140. LI KK, Trivedi PJ, Von Heimendahl S, Bruns T, et al
    Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
    Hepatology. 2016;63:1394-5.
    PubMed     Text format    


  141. CUBERO FJ
    Shutting off inflammation: A novel switch on hepatic stellate cells.
    Hepatology. 2016;63:1086-9.
    PubMed     Text format    


  142. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


    March 2016
  143. KUNIHOLM MH, Nelson KE
    Reply: Acute and Chronic Hepatitis E Virus Infection in HIV-Infected U.S. Women.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28581.
    PubMed     Text format    


  144. PONZETTO A, Carloni G
    HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28580.
    PubMed     Text format    


  145. SU TH, Chen CL, Kao JH
    RE: HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28578.
    PubMed     Text format    


  146. SPACEK LA
    Comment on: Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus-Infected U.S. Women.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28582.
    PubMed     Text format    


  147. CHHATWAL J, Wang X, Ayer T, Kabiri M, et al
    Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571.
    PubMed     Text format     Abstract available


  148. VARGAS H
    Hepatitis C Treatment In 2016: Reasons to be an OPTIMIST.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28559.
    PubMed     Text format    


  149. WROBLEWSKI R, Armaka M, Kondylis V, Pasparakis M, et al
    Opposing Role of Tumor Necrosis Factor Receptor 1 Signaling in T Cell Mediated Hepatitis and Bacterial Infection In Mice.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28551.
    PubMed     Text format     Abstract available


  150. BUTI M, Sanchez-Ruano J, Morillas RM, Esteban R, et al
    Baseline HCV-RNA levels in genotype 1 Chronic Hepatitis C Patients: The role of different cut-off points.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28544.
    PubMed     Text format    


  151. PEIFFER KH, Sommer L, Zeuzem S, Sarrazin C, et al
    Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a".
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28536.
    PubMed     Text format    


  152. EL-SERAG HB, Kanwal F, Richardson P, Kramer J, et al
    Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28535.
    PubMed     Text format     Abstract available


  153. PEDERGNANA V, Smith D, Klenerman P, Barnes E, et al
    Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28533.
    PubMed     Text format    


  154. MANDREKAR P, Bataller R, Tsukamoto H, Gao B, et al
    Alcoholic hepatitis: Translational approaches to develop targeted therapies.
    Hepatology. 2016 Mar 3. doi: 10.1002/hep.28530.
    PubMed     Text format     Abstract available



  155. Correction: Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma.
    Hepatology. 2016;63:1064.
    PubMed     Text format    


  156. DANDRI M, Bockmann JH
    The challenge of protecting without overprotecting: The two sides of myeloid-derived suppressor cells in hepatitis B viral infection.
    Hepatology. 2016;63:1043-6.
    PubMed     Text format    


  157. HOFFMANN F, Endres S, Rothenfusser S
    Reply.
    Hepatology. 2016;63:1062-3.
    PubMed     Text format    


    February 2016
  158. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  159. TANG DM, Heller T, Koh C
    The many faces of positive hepatitis B surface antigen.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28503.
    PubMed     Text format    


  160. MELLINGER J, Fontana RJ
    Quality of care metrics in chronic hepatitis B.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28500.
    PubMed     Text format    


  161. SCHNABL B
    Liver Capsule: Mechanisms Of Alcoholic Hepatitis.
    Hepatology. 2016 Feb 11. doi: 10.1002/hep.28488.
    PubMed     Text format    


  162. MARTIN NK, Vickerman P, Brew IF, Williamson J, et al
    Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis.
    Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497.
    PubMed     Text format     Abstract available


  163. LINDENBACH BD
    "What's next for hepatitis C virus research?"
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28494.
    PubMed     Text format    


  164. HEZODE C, Chevaliez S, Scoazec G, Soulier A, et al
    Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28491.
    PubMed     Text format     Abstract available


  165. HADZIC N, Bansal S
    Hepatitis B virus in children: More therapeutic options-but unknown and known unknowns still present.
    Hepatology. 2016;63:360-2.
    PubMed     Text format    


    January 2016
  166. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  167. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  168. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  169. WONG TC, Lan A, Kiser J, Anderson PL, et al
    Novel Quantification of TDF adherence in HIV-hepatitis B co-infected patients with incomplete HBV viral suppression.
    Hepatology. 2016 Jan 21. doi: 10.1002/hep.28461.
    PubMed     Text format    


  170. BOYD A, Peytavin G, Lacombe K
    Reply to: Novel Quantification of TDF adherence in HIV-hepatitis B co-infected patients with incomplete HBV viral suppression.
    Hepatology. 2016 Jan 19. doi: 10.1002/hep.28463.
    PubMed     Text format    


  171. ZHANG ZF, Duan ZJ
    A methodology concern of the meta-analysis of antiviral therapy for chronic hepatitis B virus infection in adults.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28455.
    PubMed     Text format    


  172. INNES H, Hutchinson SJ, Obel N, Christensen PB, et al
    Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland - using spontaneous resolvers as the benchmark comparator.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28458.
    PubMed     Text format     Abstract available


  173. DAHARI H, Cotler SJ, Feld JJ
    Cure prevents more than transmission of HCV.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28449.
    PubMed     Text format    


  174. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


  175. SUNAMI Y, Ringelhan M, Kokai E, Lu M, et al
    Canonical NF-kappaB signaling in hepatocytes acts as a tumor-suppressor in HBV surface antigen-driven HCC by controlling the UPR.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28435.
    PubMed     Text format     Abstract available



  176. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.
    Hepatology. 2016;63:349.
    PubMed     Text format    


  177. MERRIMAN RB, Tran TT
    AASLD practice guidelines: The past, the present, and the future.
    Hepatology. 2016;63:31-4.
    PubMed     Text format    


    December 2015
  178. DESOMBERE I, Fafi-Kremer S, Van Houtte F, Pessaux P, et al
    Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28428.
    PubMed     Text format     Abstract available


  179. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  180. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  181. JIANG DK, Wu X, Qian J, Ma XP, et al
    Genetic variation in STAT4 predicts response to interferon-alpha therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28423.
    PubMed     Text format     Abstract available


  182. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  183. GALMOZZI E
    Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28421.
    PubMed     Text format    


  184. BELAND K, Alvarez F
    Anti-CD20 monoclonal antibody for the treatment of patients with autoimmune hepatitis.
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28407.
    PubMed     Text format    


  185. SIRA MM, Sira AM
    B cell depletion in autoimmune hepatitis: Is it safe for the bowel?
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28405.
    PubMed     Text format    


  186. MEHTA N, Yao FY
    Nucleos(t)ide analogues to reduce the risk of Hepatitis B associated hepatocellular carcinoma: A can't miss proposition?
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28404.
    PubMed     Text format    


  187. LIN J, Ou HY, Chuang LM, Chiu KC, et al
    Diabetes prevention through prevention of hepatitis B.
    Hepatology. 2015 Dec 13. doi: 10.1002/hep.28399.
    PubMed     Text format    


  188. WIELAND D, Thimme R
    Vaccine-induced HCV-specific CD8+ T cells do not always help.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28388.
    PubMed     Text format    


  189. SU TH, Liu CJ, Tseng TC, Chou SW, et al
    Hepatitis C virus infection increases the risk of lymphoid-neoplasms: A population-based cohort study.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28387.
    PubMed     Text format     Abstract available


  190. CHEN DS, Liaw YF, Chen CJ, Wu JC, et al
    Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28378.
    PubMed     Text format    


  191. KUNIHOLM MH, Ong E, Hogema BM, Koppelman M, et al
    Acute and Chronic Hepatitis E Virus Infection in HIV-Infected United States Women.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28384.
    PubMed     Text format     Abstract available


  192. JARUVONGVANICH V, Upala S, Sanguankeo A
    Association between systemic inflammatory response syndrome and mortality in alcoholic hepatitis: A meta-analysis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28366.
    PubMed     Text format    


  193. SPRADLING PR, Bulkow LR, Negus SE, Homan C, et al
    Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28375.
    PubMed     Text format     Abstract available


    November 2015
  194. PISCAGLIA F, Svegliati-Baroni G, Barchetti A, Pecorelli A, et al
    Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368.
    PubMed     Text format     Abstract available


  195. LOK AS, McMahon BJ, Brown RS Jr, Wong JB, et al
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28280.
    PubMed     Text format     Abstract available


  196. JONAS MM, Lok AS, McMahon BJ, Brown RS Jr, et al
    Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28278.
    PubMed     Text format     Abstract available


  197. TERRAULT NA, Bzowej NH, Chang KM, Hwang JP, et al
    AASLD guidelines for treatment of chronic hepatitis B.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28156.
    PubMed     Text format    


  198. BROWN RS JR, McMahon BJ, Lok AS, Wong JB, et al
    Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28302.
    PubMed     Text format     Abstract available


  199. GALUN E
    Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28344.
    PubMed     Text format    


  200. CABALLERIA J
    Reply: To PMID 25502967.
    Hepatology. 2015;62:1644.
    PubMed     Text format    


  201. DITAH I, Charlton M
    Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret.
    Hepatology. 2015;62:1337-8.
    PubMed     Text format    


    October 2015
  202. PUBLICOVER J, Jespersen JM, Johnson AJ, Nishimura SL, et al
    Age-influenced hepatic immune priming determines HBV infection fate; implications from Mouse to Man.
    Hepatology. 2015 Oct 12. doi: 10.1002/hep.28284.
    PubMed     Text format    


  203. LEE TY, Lin JT, Zeng YS, Chen YJ, et al
    Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation.
    Hepatology. 2015 Oct 1. doi: 10.1002/hep.28266.
    PubMed     Text format     Abstract available


    June 2015
  204. LI M, Mennone A, Soroka CJ, Hagey LR, et al
    NHERF-1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27956.
    PubMed     Text format     Abstract available


    February 2015
  205. TRINCHET JC, Bourcier V, Chaffaut C, Ait Ahmed M, et al
    Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27743.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: